OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Company News Release
DIA global headquarters will host 18 leaders from the State Food and Drug Administration of China (SFDA). The SFDA delegation is comprised of leaders from different provinces of China as well as four individuals from the central office in Beijing. Their expertise includes drug registration and the center of control testing labs.
Prior to their arrival at DIA, the group participated in a 10-day regulatory affairs training at Yale University’s School of Public Health. Since completing the program earlier this week, the delegation has been visiting various organizations such as the NJ FDA Field Office, Novartis, the University of Sciences Philadelphia, and the United States Pharmacopeia (USP). SFDA participants include:
“DIA is a global community that shares knowledge, cultivates relationships, and facilitates dialogue among regulators across and within all geographic regions,” says Paul Pomerantz, DIA Worldwide Executive Director.” We are pleased to welcome representatives from SFDA to our global headquarters to explore how our organizations can continue to work together to educate our industry about reporting, compliance and other requirements and developments around the world.”
In addition, three executive team members from the Sino-American Pharmaceutical Professionals Association of Greater Philadelphia (SAPA GP) will be in attendance.
Related Content:
News